- Home
- ONMD vs BIAF Comparison
ONMD vs BIAF Comparison
Compare ONMD & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- BIAF
- Stock Information
- Founded
- ONMD 2006
- BIAF 2014
- Country
- ONMD United States
- BIAF United States
- Employees
- ONMD N/A
- BIAF N/A
- Industry
- ONMD
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ONMD
- BIAF Health Care
- Exchange
- ONMD Nasdaq
- BIAF Nasdaq
- Market Cap
- ONMD 12.2M
- BIAF 12.2M
- IPO Year
- ONMD N/A
- BIAF 2022
- Fundamental
- Price
- ONMD $0.46
- BIAF $0.21
- Analyst Decision
- ONMD
- BIAF Hold
- Analyst Count
- ONMD 0
- BIAF 1
- Target Price
- ONMD N/A
- BIAF N/A
- AVG Volume (30 Days)
- ONMD 100.1K
- BIAF 880.8K
- Earning Date
- ONMD 04-15-2025
- BIAF 05-15-2025
- Dividend Yield
- ONMD N/A
- BIAF N/A
- EPS Growth
- ONMD N/A
- BIAF N/A
- EPS
- ONMD N/A
- BIAF N/A
- Revenue
- ONMD $643,000.00
- BIAF $9,362,022.00
- Revenue This Year
- ONMD N/A
- BIAF N/A
- Revenue Next Year
- ONMD N/A
- BIAF $19.99
- P/E Ratio
- ONMD N/A
- BIAF N/A
- Revenue Growth
- ONMD N/A
- BIAF 269.68
- 52 Week Low
- ONMD $0.30
- BIAF $0.16
- 52 Week High
- ONMD $3.37
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- ONMD 50.88
- BIAF 32.36
- Support Level
- ONMD $0.38
- BIAF $0.19
- Resistance Level
- ONMD $0.47
- BIAF $0.24
- Average True Range (ATR)
- ONMD 0.04
- BIAF 0.04
- MACD
- ONMD 0.02
- BIAF -0.02
- Stochastic Oscillator
- ONMD 89.29
- BIAF 11.72
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its innovative solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols and paves the way for Real World Evidence.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.